高级检索

神经内科住院患者并发静脉血栓栓塞症的临床特征分析

Clinical characteristics of inpatients complicated with venous thromboembolism in the department of neurology

  • 摘要:
    目的 探讨神经内科住院患者并发静脉血栓栓塞症(venous thromboembolism,VTE)的临床特征、治疗策略和出血风险。
    方法 回顾性分析2014年1月至2020年12月复旦大学附属中山医院收治的77例神经内科住院患者并发VTE的临床特征及治疗预后。
    结果 77例患者中,男性43例,女性34例,平均年龄(69.0±11.9)岁。最常见的神经内科基础疾病为缺血性脑卒中、脑出血、中枢神经系统感染和脊髓病变,总死亡率为2.6%(2/77)。明确诊断为肺动脉栓塞(pulmonary embolism,PE)的患者62例(80.5%),深静脉血栓(deep venous thrombosis,DVT)患者40例(51.9%),两者同时发生者25例(32.5%)。有临床症状的PE患者14例(22.6%),有临床症状的DVT患者5例(12.5%)。所有患者入院时D-二聚体水平为(4.9±6.7)mg/L,确诊为VTE时D-二聚体水平为(11.7±9.9)mg/L。缺血性脑卒中组、脑出血组和其他少见疾病组3组的出血事件发生率为20.0%、37.5%和20.8%,有临床意义的严重出血事件发生率为7.5%、25.0%和12.5%,差异均无统计学意义。对所有接受抗凝患者进行HAS-BLED出血风险评估,低风险组(< 3分)共38例(52.8%),高风险组(≥3分)共34例(47.2%),出血风险差异无统计学意义。
    结论 神经内科患者VTE发病隐匿,需要建立对此类患者的亚临床VTE筛查策略;抗凝治疗有一定的出血风险,应合理评估利弊。

     

    Abstract:
    Objective To explore the clinical characteristics, treatment strategies and bleeding risk of inpatients complicated with venous thromboembolism (VTE) in the department of neurology.
    Methods The clinical features and treatment outcomes of patients with VTE events in the Department of Neurology of Zhongshan Hospital, Fudan University from January 2014 to December 2020 were retrospectively analyzed.
    Results A total of 77 patients were collected, including 43 males and 34 females, with an average age of (69.0±11.9) years. The most common underlying diseases of the neurology department were ischemic stroke, cerebral hemorrhage, central nervous system infection, and myelopathy. The overall mortality rate was 2.6%(2/77). There were 62 (80.5%) patients with pulmonary embolism (PE), 40(51.9%) patients with deep vein thrombosis (DVT), 25(32.5%) patients with both PE and DVT, 14(22.6%) PE patients with clinical symptoms, and 5(12.5%) DVT patients with clinical symptoms. The D-dimer level of all patients was (4.9±6.7) mg/L at admission and (11.7±9.9) mg/L at the diagnosis of VTE. For ischemic stroke, cerebral hemorrhage, and other rare diseases, the incidence of bleeding events in the three groups was 20%, 37.5%, and 20.8%, respectively, and the incidence of clinically significant severe bleeding events in the three groups was 7.5%, 25%, and 12.5%, respectively. There was no significant difference in the incidence among the three groups. The bleeding risk of all patients receiving anticoagulant was assessed by HAS-BLED. A total of 38 patients (52.8%) were in the low-risk group (< 3 points) and 34 patients (47.2%) in the high-risk group (≥ 3 points). There was no significant difference in the bleeding risk between the two groups.
    Conclusions The occurrence of VTE in neurology patients is occult, and VTE screening strategy should be established for these subclinical patients. Anticoagulant therapy has a certain risk of bleeding, and the benefit-risk balance should be properly evaluated.

     

/

返回文章
返回